Bicycle Therapeutics (BCYC) Non-Current Deffered Revenue (2018 - 2026)

Bicycle Therapeutics (BCYC) has 9 years of Non-Current Deffered Revenue data on file, last reported at $34.3 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Deffered Revenue fell 58.23% year-over-year to $34.3 million; the trailing twelve-month figure through Mar 2026 stood at $34.3 million (down 58.23% YoY), and the FY2025 full-year result was $35.5 million, down 61.18% from the prior year.
• Non-Current Deffered Revenue for Q1 2026 stood at $34.3 million, down from $35.5 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $115.1 million in Q2 2023 and bottomed at $34.3 million in Q1 2026.
• The 5-year median for Non-Current Deffered Revenue is $82.9 million (2025), against an average of $75.5 million.
• The widest annual swing landed in 2023, when Non-Current Deffered Revenue jumped 165.87%; it then sank 61.18% in 2025.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $41.5 million in 2022, then jumped by 165.87% to $110.2 million in 2023, then slipped by 17.01% to $91.5 million in 2024, then sank by 61.18% to $35.5 million in 2025, then fell by 3.29% to $34.3 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $34.3 million (Q1 2026), $35.5 million (Q4 2025), and $74.1 million (Q3 2025), per Business Quant data.

Peer Comparison